Why Most Licensing Term Sheets Die in Negotiation (And How to Rescue Them)

Most university licensing deals don't die in due diligence. They die in the room where the term sheet gets opened.

Photo by Markus Winkler on Pexels.

That's not a dramatic claim, it's a pattern that anyone who has spent time inside a tech transfer office will recognize immediately. The science is sound, both parties want a deal, and then something goes sideways between the first meeting and the signed agreement. Months pass. Emails go unanswered. The startup raises a bridge round and quietly lets the option expire.

So what's actually happening?

The Royalty Rate Obsession

Ask most TTOs what they fight hardest for in a licensing negotiation and they'll say royalty rates. It makes sense on paper, royalties are the visible number, the one that shows up in annual reports, the metric boards ask about. But royalty rates are often the least consequential variable in whether a deal creates real value.

A 4% royalty on a product that reaches market beats a 6% royalty on a product that never gets there. Every time. What actually determines whether a licensee invests seriously in development milestones, commercialization timelines, and sublicensing rights, not the percentage point battle that consumes two months of back-and-forth.

When negotiators anchor too hard on royalty rates, they signal that they're optimizing for revenue extraction rather than commercial success. That signal lands badly with early-stage companies that are already terrified of fixed obligations.

The Scope Problem Nobody Talks About

Here's where deals quietly collapse: field-of-use and territory definitions.

A university wants broad scope to protect optionality. A startup wants narrow, exclusive rights in the fields where they actually intend to compete, because exclusivity in the right field is worth more than non-exclusive rights across ten fields they'll never enter. When these two positions meet in a term sheet, you often get language so vague that both parties think they won.

Then, eighteen months later, someone else licenses adjacent technology and the startup's investors ask hard questions about freedom to operate. Trust erodes. Sometimes litigation follows.

Getting specific about scope upfront is painful and slow. It requires the licensee to actually articulate their business plan in technical terms, and it requires the TTO to understand that plan well enough to map it to the patent claims. Most offices don't staff for that depth of engagement. So the vague language stays, and the detonator gets buried in the agreement.

What Milestone Structures Actually Communicate

Development milestones are where the deal either gets real or gets fictional.

A milestone schedule is not just a legal tool for maintaining exclusivity, it's the document that tells you whether a licensee has actually thought through their development path. Vague milestones ("achieve proof of concept by month 18") are a red flag. They mean the company hasn't pressure-tested its timeline, or worse, that they negotiated the milestones down until they were meaningless.

TTOs that accept weak milestone language in exchange for a faster close are making a trade that rarely pays off. What they get is a signed agreement. What they lose is any leverage to push the licensee toward genuine commercialization effort.

The better approach: treat milestone negotiation as a diligence conversation. If a company can't defend a specific milestone with a specific rationale, that tells you something important about execution capacity, before you're locked into a ten-year exclusive agreement with them.

A Cleaner Path Through Negotiation

The deals that close and actually work tend to follow a different sequence than the ones that stall.

graph TD
    A[Early Technical Briefing] --> B{Commercial Fit Assessment}
    B --> C[Term Sheet Draft, Milestones First]
    C --> D[Scope and Field Alignment]
    D --> E[Royalty and Financial Terms]
    E --> F[Signed License Agreement]
    F --> G((Active Commercialization))

Notice what's not at the top: royalties. When financial terms come last, after both parties have genuinely aligned on scope, milestones, and commercial intent, they tend to resolve faster. The number feels like a detail once the hard structural questions are settled.

Starting with milestones forces the licensee to show their thinking early. It also helps TTOs identify which deals deserve heavy investment of staff time and which should stay as non-exclusive, low-touch arrangements.

The Relationship Variable

None of this is purely transactional, and pretending otherwise is where a lot of TTOs get into trouble.

The person across the table from a licensing manager is often a founder who's terrified of existential legal obligations, or a business development executive at a company where this deal is one of forty on their plate. Neither of them responds well to adversarial posturing. Both of them have options.

Universities that build reputations as collaborative, reasonable partners get called first when companies are scouting technology. Universities that are known for aggressive extraction, where every negotiation feels like a hostage situation, get avoided, and their deal flow reflects it.

Reputation compounds. Slowly, and then all at once.

The goal isn't to be a pushover. It's to be the kind of counterparty that serious companies want to work with, because that's what actually converts discovery into market impact.